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MRSA against antibiotics.
Materials and Methods: MRSA from sterile sites were collected from 22 hospi-
tals (Tigecycline In-vitroSurveillance inTaiwane TIST 2006-2010) and tested of
MIC against antibiotics with variable AST: agar dilution for oxacillin (OX) and
vancomycin (VA); Etest for VA and daptomycin (DAP), and Vitek-II automated
system for OX, VA, and DAP. Molecular types including SCCmec, spa, and dru
were determined by PCR and nucleotide sequencing. The differences of MICs
by various AST and correlation of MICs with molecular types were analyzed.
Results: Totally, 670 mecA+ MRSA from sterile sites were collected. The
MIC50/MIC90 against VA by agar dilution, Etest, and Vitek-II were 1.5/2, 2/
2 and 1/1 mg/L, respectively. The DAP MIC50/MIC90 by Etest and Vitek-II
were 0.25/0.38 and 1/1 mg/L, respectively. The OX MIC50/MIC90 by agar dilu-
tion and Vitek-II were 256/>256 and S4/S4 mg/L, respectively. The VA
arithmetic/geometric mean MICs by Etest (1.87/1.81 mg/L) were higher
than agar dilution (1.42/1.36 mg/L) and Vitek-II (0.94/0.87 mg/L) (p <
0.001). In contrast, the DAP arithmetic/geometric mean MICs by Etest
(0.28/0.24 mg/L) were lower than Vitek-II (0.79/0.67 mg/L) (p < 0.001).
The number of OX MIC S4 mg/L (i.e., resistant phenotype) by agar dilution
was more than Vitek-II (p < 0.001). Higher VA MICs were noted in molecularly
HA-MRSA (e.g., SCCmecII & III; spa t002 & t037; dru4, 13, and 14) than CA-
MRSA (e.g., SCCmecIV, V, and VT; spa t437 & t1081; dru9 & 11) (p < 0.05).
Conclusions: Significant differences between AST against VA, DAP, and OX
were found among MRSA. Increase in VA MIC may predict treatment failure
in patients infected with HA-MRSA.PS 1-185
EVALUATION OF CEFTAROLINE ACTIVITY AGAINST METHICILLIN
RESISTANT STAPHYLOCOCCUS AUREUS IN A REGIONAL HOSPITAL IN
HONG KONG
Christopher K. C. Lai, Johnson K. S. Lam, W. H. Ng, Ricky K. W. Lam, Dominic
N. C. Tsang. Department of Pathology, Queen Elizabeth Hospital, Hong Kong
Purpose: Ceftaroline fosamil is a new cephalosporin with broad spectrum
bactericidal activities against a broad range of organisms including methi-
cillin-resistant S.aureus (MRSA). It was approved in the USA and European
countries in 2010 and 2012 for acute bacterial skin and soft tissue infections
and community acquired pneumonia. It was registered in Hong Kong in 2013
and its activity against local strains, especially MRSA, remained uncertain.
Methods: We prospectively retrieved 61 isolates of MRSA and 6 isolates of
methicillin sensitive S.aureus MSSA recovered from blood cultures (unique
by patient) received in Queen Elizabeth Hospital, Hong Kong, between
2013 and 2014. Bacterial isolates were tested for susceptibility to ceftaroline
according to disk diffusion methods of the Clinical and Laboratory Standards
Institute (CLSI). QC strains included S.aureus ATCC 25923 and S.epidermidis
ATCC 12228 were used. All QC results were within published CLSI ranges.
Results: Out of the 61 MRSA tested, 1.6% (1/61) was resistant ceftaroline,
4.9% (3/61) of the isolates were intermediate, and the remaining 93.4%
(57/61) remained susceptible. All the 6 MSSA strains tested were sensitive
to ceftaroline.Figure.1 Susceptibility of 61 strains of MRSA against Ceftaroline.Conclusion: The local strains of MRSA are not universally susceptible to Cef-
taroline, antimicrobial susceptibility test must be performed before decision
to switch to this agent.PS 1-186
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Purpose: The plasmid-borne extended-spectrum b-lactamases (ESBLs) and
AmpC b-lactamases in Enterobacter spp have been reported in recent years
in Taiwan and may result in diagnostic and therapeutic challenges. In this
study, we detected the plasmid-borne AmpC b-lactamase and ESBL genes
from Enterobacter cloacae bloodstream isolates in a medical center in
southern Taiwan.
Material and methods: A total 41 non-repetitive blood isolates of E. cloacae
resistant to ampicillin, cefazolin and ceftazidime were investigated. ESBL
and AmpC resistance genes were detected from plasmid using multiplex
PCRs and DNA sequencing. A series of primers were used to detect the
ESBL (SHV, TEM and CTX-M) and AmpC (ACT, DHA, and MIR) b-lactamase
genes. Conjugation experiments were conducted to confirm the resistant
gene transferability.
Results: Detection of plasmid-borne genes included blaSHV-12 (48.8%, 20/41);
blaTEM (22%, 9/41); blaCTX-M-3 (2.4%, 1/41) and blaampC (73.2%, 30/41),
including blaACT (n Z26) and blaDHA-1 (n Z3). The blaTEM-1 was detected in
7 isolates, in which 4 isolates also harbored a blaampC and a blaSHV-12, and
the other 3 isolates harbored an additional blaampC. Two novel plasmid-medi-
ated ampC genes designed blaCMH-1 (GenBank accession number JQ673557)
and blaMIR-6 (GenBank accession number JQ664733) were detected. The
blaCMH-1 gene has a 99% similarity to a chromosome-borne ampC gene in E.
cloacae ATCC 13047 strain, and has a 90% similarity to a novel blaMIR-8
gene from plasmid of K. pneumoniae. The ampC-encoded plasmids
(including blaCMH-1) could be successfully conjugated in the experiments.
Conclusions: The blaACT was highly prevalent and blaCMH-1 and blaMIR-6 first
emerged in E. cloacae.PS 1-187
USE OF INFORMATION SYSTEMS TO IMPROVE THE INCIDENCE OF CRAB
Wanling Tai. Chiayi Chang Gung Memorial Hospital, Taiwan, ROC
Purpose: CRAB Regional Hospital in Taiwan by 2004 to increase the propor-
tion of nosocomial infection surveillance in accordance with the Taiwan In-
formation Systems (TNIS) data show that 34% to 77% in 2013. Court from 2008
to 2011 the whole hospital isolates of drug susceptibility testing Acineto.-
baumannii for Carbapenem (imipenem or meropenem) drug susceptibility
testing is reduced from 97% to 60%, we can see there is an apparent increase
in hospital CRAB trends (2011 ICU detection rate of 45.5%).
Methods: When to validate the test results, it will use the computer to
"dangerous values notification system" will be resistant to the message is-
sued by the hospital Medical laboratory scientist warning to inform clinical
unit, on-site contact isolation precautions will be taken immediately
informed of the message, and to remind physicians to open a contact isola-
tion doctor’s advice.
Results: 2012 and the first half of the hospital CRAB detection ratio
comparing the first half of 2011 decreased by 44% to 32%. Continuously
monitor hospital ICU healthcare associated infections CRAB strains have
been detected in the ratio of 45.5% in 2011 to 20% in 2013.
Conclusions: A wide range of drug-resistant strains have been omnipresent,
how to avoid its spread and cause bunching, is a major challenge we have to
face, only the continued implementation of the relevant constant sense and
evaluate the effectiveness of control measures and whether they implement
it, can only provide a good healthcare environment and enhance patient
safety.
